This new formulation represents a significant improvement over protease inhibitor-containing paediatric ARV formulations that have been used in South Africa for decades.
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
CerTest Biotec uses the BD MAX molecular diagnostic system open system reagent suite to develop RT-PCR detection kit
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
To address the preventive & primary healthcare delivery gaps in India
Report lays out blueprint for achieving Organon’s purpose and business imperatives to help women and girls achieve their promise through better health
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
This expansion announcement came right after raising series B funding of $27 Mn in a round led by Fundamentum Partnership, earlier this month.
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
Subscribe To Our Newsletter & Stay Updated
